ArticleArchives of virology2009
Characterization of SARS-CoV-specific memory T cells from recovered individuals 4 years after infection.
Article in Archives of virology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 159 citations in OpenAlex.
- Dynamic shifts in lung cytokine patterns in post-COVID-19 interstitial lung disease patients: a pilot study.Therapeutic advances in chronic disease · 2024Article
- Design and Assessment of a Novel In Silico Approach for Developing a Next-Generation Multi-Epitope Universal Vaccine Targeting Coronaviruses.Microorganisms · 2023Article
- Effect of probiotics as an immune modulator for the management of COVID-19.Archives of microbiology · 2023Article
- Early protective effect of a ("pan") coronavirus vaccine (PanCoVac) in Roborovski dwarf hamsters after single-low dose intranasal administration.Frontiers in immunology · 2023Article
- Mucosal immunization with lipopeptides derived from conserved regions of SARS-CoV-2 antigens induce robust cellular and cross-variant humoral immune responses in mice.Frontiers in immunology · 2023Article
- Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy.International journal of molecular sciences · 2022Review
- Adaptive Immunity to Viruses: What Did We Learn from SARS-CoV-2 Infection?International journal of molecular sciences · 2022Review
- Gene Signatures of T-Cell Activation Can Serve as Predictors of Functionality for SARS-CoV-2-Specific T-Cell Receptors.Vaccines · 2022Article
- The effect of age on the magnitude and longevity of Th1-directed CD4 T-cell responses to SARS-CoV-2.Immunology · 2022Article
- T cell responses to SARS-CoV-2 in humans and animals.Journal of microbiology (Seoul, Korea) · 2022Review
- Review
- Peculiarities of the T Cell Immune Response in COVID-19.Vaccines · 2022Review
- Immune interventions in COVID-19: a matter of time?Mucosal immunology · 2022Review
- COVID-19: Immunology, Immunopathogenesis and Potential Therapies.International reviews of immunology · 2022Review
- The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection.Frontiers in immunology · 2022Review
- SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases.Journal of translational autoimmunity · 2022Article
- An overview of the recent findings of cell-based therapies for the treatment and management of COVID-19.International immunopharmacology · 2021Review
- Pathogenesis of covid - 19 - Pandemonium of the pandemic in Pandora's box.Journal of family medicine and primary care · 2021Review
- Possible therapeutic effects ofPharmaceutical biology · 2021Review
- Immune response variables and viral mutations impact on COVID-19 reinfection and relapse.International immunopharmacology · 2021Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
SARS-CoV infection of human results in antigen-specific cellular and humoral immune responses. However, it is critical to determine whether SARS-CoV-specific memory T cells can persist for long periods of time. In this study, we analyzed the cellular immune response from 21 SARS-recovered individuals who had been diagnosed with SARS in 2003 by using ELISA, CBA, ELISpot and multiparameter flow cytometry assays. Our results demonstrated that low levels of specific memory T cell responses to SARS-CoV S, M, E and N peptides were detected in a proportion of SARS-recovered patients, and IFN-gamma was the predominant cytokine produced by T cells after stimulation with peptides. Cytometry analysis indicated that the majority of memory CD8(+) T cells produced IFN-gamma, whereas memory CD4(+) T cells produced IFN-gamma, IL-2 or TNF-alpha. These results might provide valuable information on the cellular immune response in recovered SARS-CoV patients for the rational design of vaccines against SARS-CoV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.